Results: Based on sensitivity assays, 8 top-ranking markers were identified: CCND1, CRMP1, DDC, GABRB3, ISL1, KIF1A, PHOX2B, and TACC2. Top ranking markers were then tested for prognostic significance in the marrows of stage 4 patients collected from the same treatment protocol after two cycles of immunotherapy. Quantitative reverse transcription-PCR was done on all 34 genes to study the dynamic range of tumor cell detection and the expression of these genes in normal marrow/blood samples and in stage 4 neuroblastoma tumors. Thirty-four genes with a tumor-to-marrow expression ratio higher than tyrosine hydroxylase were identified. Genome-wide expression profiling can uncover potential MRD markers differentially expressed in tumors over normal marrow/blood.Įxperimental Design: Gene expression array was carried out on 48 stage 4 tumors and 9 remission marrows using the Affymetrix U95 gene chip. Because of tumor heterogeneity, no single marker will likely be adequate.
Evaluating treatment efficacy requires MRD measurement, which serves as surrogate endpoint.
Biological therapies directed against MRD can improve outcome. Purpose: Minimal residual disease (MRD) presents a significant hurdle to curing metastatic neuroblastoma.
0 kommentar(er)
